At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 98 enrolled
Drug / intervention
Fingolimod 0.5mgdrug
Likely dose
Fingolimod 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Relapsing Multiple Sclerosis (RMS) Patients in China
In Brief
A Phase 4 clinical trial evaluating Fingolimod 0.5mg for Relapsing Multiple Sclerosis (RMS). Completed, enrolled 98 participants across 13 sites.
Detailed Summary
The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Multiple Sclerosis (RMS)
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionMar 2025
TodayJul 2026
First PostedDec 16, 2020
Enrollment StartFeb 20, 2021
Primary CompletionMar 25, 2025
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 5.5 years ago
Interventions
Fingolimod 0.5mgdrug
Subjects received fingolimod 0.5mg capsule QD up to month 24